To date, four genome screens have been completed in the demyelinating autoimmune disease multiple sclerosis (MS). Although these screens failed to identify any loci with major effects on susceptibility, several novel regions of potential linkage were suggested, including the long arm of chromosome 17. In order to further pursue this promising region we have investigated six highly polymorphic microsatellite markers in 115 Scandinavian families with MS affected sib pairs. Multipoint linkage analysis revealed a peak maximum likelihood score (MLS) of 0.9 in the region of marker D17S787. Stratifying the results on the basis of HLA-DR2 status showed that the linkage was not limited to families segregating for the HLA-DR2 allele as has previously been suggested. In conclusion, our results further support the proposal that a multiple sclerosis susceptibility locus is contained on chromosome 17q. Genes and Immunity (2000) 1, 456-459.
Introduction
Multiple sclerosis (MS) is the most frequent chronic disabling disorder of the central nervous system to affect young adults. The exact ethiology of the disease is unknown, but evidence from family studies [1] [2] [3] [4] [5] indicates a strong genetic component. So far, however, the only consistent observation from the genetic analysis of the disease is its association with alleles of the HLA system on chromosome 6p21. Four whole genome screens have been completed in MS, three based on large outbred populations from the United Kingdom, the United States and Canada/France, and one based on a small isolated population from Finland. [6] [7] [8] [9] Although no statistically unequivocal linkage was observed in any of these screens, each identified a number of potential linkage regions, many of which were not previously suspected to contain MS susceptibility genes. Some evidence for the involvement of the HLA system was found in each of the screens, and the data supporting this established region has continued to grow. [10] [11] [12] [13] In the British study the best supported region outside HLA was on chromosome 17q where a final maximum likelihood score (MLS) of 2.7 was observed. 6 Evidence supporting this region was also found in the Finnish screen, 9 making 17q one of the best supported novel linkages. The high prevalence of MS in Scandinavia (0.1%) 14 makes this population ideal for the further analysis of a candidate region such as 17q. We have now analysed this region in 115 Caucasian Scandinavian families with affected sib pairs using six microsatellite markers. In addition we have stratified these data on the basis of DR2 sharing in order to look for evidence of interaction with HLA.
Results and discussion
The characteristics of the Scandinavian families and individuals investigated are given in Table 1 . The results of our linkage analysis on chromosome 17q are summarised in Figure 1 , which shows the maximum likelihood score (MLS) map for the region. The MLS profile exceeded the 5% nominal significance level over an 8 cM interval and peaked at a value of 0.9 in the vicinity of the D17S787 marker. To address the possible interaction with HLA, all families were typed for the presence of HLA-DR2. In 67 families the sib pairs were DR2-concordant positive, based on the identical by state status. These families gave a peak MLS of only 0.2. However, when excluding these HLA DR2 status n of DR2 negative 29 n of DR2 concordant 67 n of DR2 discordant 20
All patients had clinically definite MS according to the Poser criteria. 15 Sib pairs from Denmark and Norway were collected from the whole country, whereas sib pairs from Sweden were recruited from the Lund and Stockholm areas and the Finnish sib pairs were from the southern part of Finland not previously included in the Finnish genome screen. A total of 115 Caucasian families (yielding the equivalent of 126 sib pairs) were included in the study. Blood from all available parents and from unaffected siblings where parents were missing was sampled as well. A total of 326 individuals were recruited in this study.
families and repeating the linkage analysis in the remaining 49 families, a peak MLS of 0.9 was still observed around D17S787. Strikingly, for the 29 families with HLA-DR2-negative sib pairs a peak MLS of just 0.2 was obtained, while the 20 HLA-DR2 discordant sib pair families yielded a peak MLS of 0.8 and thus contributed most to the combined MLS.
Each of the four MS genome screens published so far reported several MS susceptibility loci. Three genome regions: 6p21 (the HLA-region), 5p and 17q were positive in more than one data set. We have recently published evidence supporting the existence of a multiple sclerosis susceptibility gene on two of these loci, i.e. the HLAregion on 6p21 and 5p. Evidence of an MS susceptibility locus on chromosome 17q was found in the British 6 and Finnish 9 genome screens. In the different studies, peak values of maximum likelihood score (MLS) were found for different markers located in the same chromosomal region, ie 17q22-24. In the present study, the marker showing the highest MLS is D17S787. However, the marker having a high lod score in the British and Finnish studies (D17S807) has a very low lod score in our study. We have analysed the Danish families and the rest of the Scandinavian families separately and found linkage to the D17S787 marker in both groups and no linkage to the D17S807. Because it is recognised that peaks of linkage in polygenic disease only define a confidence interval for the location of a gene rather than a critical region in which the gene must lie, susceptibility genes may map near to peaks of linkage rather than directly under them. 18, 19 We can therefore confirm the presence of an MS susceptibility gene on 17q22.
Stratification by excluding the DR2 sharing sib pairs did not change the MLS. However, it is quite striking that
Genes and Immunity the 20 families with DR2 discordant sibpairs contributed most positively to the combined MLS value of 0.9, and it may be speculated that the effect of polymorphic genes on chromosome 17 has a better chance of manifesting itself, when that of HLA linkage is minimised. These results may be related to our findings on chromosome 5 where we found MLS to be independent of DR2 status, 13 thus suggesting DR2 independent genes on both 17q and 5p. However, the present results differ from those of Coraddu et al. 10 in the UK data from chromosome 17q where the linkage seemed to be confined to those families sharing the extended DR2 haplotype.
In a very recent study Fontaine et al 20 failed to find any evidence of excess sharing in the 17q22 region in 88 French multiple sclerosis families and found only very modest excess sharing in 90 American families they also studied (MLS 0.1). Combining their two data sets they estimated that s in the region is therefore likely to be less than 1.4. Genes with effects of this size would be expected to give variable evidence for linkage in modestly powered studies.
One reason for the lack of agreement among the four genome screens (including chromosome 17) could be disease heterogeneity in the investigated populations. Since MS is known to be a polygenic disease and there are two major clinical MS subtypes: Primary progressive (progression from onset) and relapsing-remitting/ secondary progressive MS, several pathogenic subtypes may exist. Unfortunately the data on clinical concordance within families with MS is very weak 21 and conflicting and cannot be taken to support the distinction between primary progressive and relapsing-remitting/secondary progressive disease. In any case, further subdivisions are unlikely to give meaningful differences in our Table 2 for properties of markers) from the region of interest identified by the British genome screen. 6 The markers cover a 32 cM region of chromosome 17q with an average intermarker separation of 6.4 cM (4-13 cM). PCR products were electrophoresed using an ABI 373 automated sequencer (Applied Biosystems, Perkin Elmer, Foster City, USA). Allele sizing and typing were performed using the semiautomatic programs Genescan 672 and Genotyper, version 2.0 software (Applied Biosystems). Typing of HLA-DR genes was carried out by standard techniques based on PCR and detected by sequence specific oligonucleotide hybridization (SSO). 16 Linkage analysis was performed using the affected sib pair method. In families where parental genotyping data are missing the probability of IBD sharing were calculated from the family data using the SPLINK program (version 1.04). 17 We used the non-parametric multipoint sib pair program MAPMAKER/SIBS (version 1.0) 18 to increase the information extracted from families by performing a multipoint analysis by combining knowledge of the genetic map with the sharing observed at flanking markers. The x axis gives chromosome position (in cM) and markers are shown below. The horizontal line indicates the 5% nominal significance level. material. It is also worth noting that in our population most of the excess sharing at this locus was seen in those sib pairs discordant for HLA-DR2. It would be interesting to see the result of a similar stratification in the American-French sample.
The gene cluster for the chemokines (cytokines of importance for inflammation) is located on chromosome 17q. Recently, it has been suggested that chemokines and their receptors play a role in the pathogenesis in MS patients, 22, 23 and genetic polymorphism in the chemokine receptors has been found to have effect on disease activity in MS patients. 24 Thus chemokines or their receptors may be of importance for the development, the disease activity, and the different courses of MS. Other candidates also map to this region however including the gene for myeloperoxidase which has been implicated in MS previously. 25, 26 
